JP Morgan Chase’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

JP Morgan Chase’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-670,000	Closed	-$9.48M	–	4388
2014 Q4	$9.48M	Buy	670,000 +165,000	+33%	+$2.56M	﹤0.01%	1988
2014 Q3	$6.94M	Buy	+505,000	New	+$7.73M	﹤0.01%	2164

JP Morgan Chase's KERX Position: Q4 2018 in Review

JP Morgan Chase sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 26,969 shares — an estimated $92K sold.

JP Morgan Chase first reported a position in KERX in Q2 2013 and held it in 20 quarters. The position peaked at $30M in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

JP Morgan Chase reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
JP Morgan Chase sold 26,969 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $92K.
JP Morgan Chase first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 20 quarters.
JP Morgan Chase's Keryx Biopharmaceuticals Inc position peaked at $30M in Q3 2013.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on JP Morgan Chase's 13F filing for Q4 2018, filed 11 Feb 2019.